Johnson and Johnson 2006 Annual Report Download - page 29

Y E A R I N R E V I E W
New Atypical
Anti-Psychotic
Reinforces
Leadership in
Psychiatry
Our long-standing leadership
position in diseases of the
central nervous system (CNS)
and, specifically, psychiatry
was further strengthened
in 2006 by the FDA
approval of INVEGA
™
(paliperidone)
Extended-Release
Tablets, a new
atypical antipsychotic
for the treatment of
schizophrenia, and by
the very important approval
for RISPERDAL
®
(risperidone),
for the treatment of irritability
associated with autistic
disorder.
INVEGA
™
represents
an important step forward
in satisfying unmet needs
in the treatment of
schizophrenia. The once-
daily oral medication is
specifically designed to deliver
paliperidone—the active
metabolite of risperidone—
through the innovative OROS
®
extended-release technology,
demonstrating powerful
efficacy and a clinically proven
safety and tolerability profile.
A long-acting formulation,
containing paliperidone
palmitate, is
not far behind.
Johnson & Johnson
Pharmaceutical
Research and
Development, LLC
expects to file a new
drug application for
paliperidone palmitate, which
is administered by injection
once every four weeks, by the
end of 2007.
Meanwhile, the
RISPERDAL
®
(risperidone)
franchise (RISPERDAL
®
and
RISPERDAL
®
CONSTA
™
Long-
Acting Injection) continues
to perform strongly with
the most-prescribed and
fastest-growing treatment
in schizophrenia. In 2006,
RISPERDAL
®
became the
first and only medication
approved by the FDA for
the treatment of irritability
associated with autistic
disorder—including
symptoms of aggression,
deliberate self-injury, temper
tantrums and quickly changing
moods—in children and
adolescents aged 5 to 16 years.
Also in 2006, two
additional dosage strengths
(3 mg and 4 mg) of
RISPERDAL
®
M-TAB
®
, the fast-
dissolving form of RISPERDAL
®
(risperidone), were made
available by prescription.
This convenient delivery form
makes taking medication
easy for patients because it
dissolves in seconds when
placed on the tongue. This is
an alternative for patients who
have difficulty or do not like
swallowing pills.
RNAi Pioneer Craig Mello Named Inaugural Winner
of Dr. Paul Janssen Award for Biomedical Research
A new award established by Johnson & Johnson to honor Dr. Paul Janssen,
one of the 20th century’s most innovative and inspiring pharmaceutical
researchers and founder of Janssen Pharmaceutica, was presented to its
inaugural recipient, Craig C. Mello, Ph.D., for his role in the discovery of RNA
interference (RNAi) and the elucidation of its biological functions. Dr. Mello
is a professor of molecular medicine at the University of Massachusetts
Medical School in Worcester, Mass., and an investigator at the Howard
Hughes Medical Institute. Shortly thereafter, Dr. Mello and his colleague
Andrew A. Fire of Stanford University were awarded the Nobel Prize
in Physiology or Medicine for 2006 for the same discovery.
Ortho-McNeil, Inc.
Signs Deal for
Worldwide Rights to
Two Type 2 Diabetes
Compounds
A licensing agreement
between Ortho-McNeil, Inc.
and Metabolex, Inc.
yielded two investigational
compounds currently in
clinical development for
the treatment of type 2
diabetes. Ortho-McNeil
secured exclusive world-
wide development and
commercialization rights
from Metabolex for these two
compounds, which represent
a novel class of insulin
sensitizers.
In all, in-licensing added
four products to the Rx
pipeline. (For more details,
see pages 26 and 28.)
27
Other
$5,784
(1.1%)
REMICADE®
$3,013
+18.9%
TOPAMAX®
$2,027
+20.7%
LEVAQUIN®/
FLOXIN®
$1,530
+2.5%
DURAGESIC®/
Fentanyl
Transdermal
$1,295
(18.3%)
ACIPHEX®/
PARIET®
$1,239
+6.0%
Hormonal
Contraceptives
$1,016
(10.6%)
RISPERDAL®/
RISPERDAL® CONSTA®
$4,183
+17.8%
PROCRIT®/
EPREX®
$3,180
(4.3%)
Pharmaceutical Segment Sales
Sales by Major Product
2006 Sales: $23,267 million Growth Rate: 4.2%
(in millions of dollars)